Sanifit appoints Preston S. Klassen MD, MHS as Chief Medical Officer and announces new US Subsidiary - Gilde Healthcare

Sanifit appoints Preston S. Klassen MD, MHS as Chief Medical Officer and announces new US Subsidiary

June 7, 2016

Former Head of R&D at Orexigen Therapeutics and Therapeutic Area Head for Nephrology at Amgen appointed as CMO

CMO appointment and launch of US subsidiary are significant steps in establishing a US presence

Palma de Mallorca, Spain – Laboratoris Sanifit S.L., a clinical-stage biopharmaceutical company focused on treatments for calcification disorders, today announces the appointment of Dr Preston S. Klassen, MD, MHS as its Chief Medical Officer and the launch of its US Subsidiary Sanifit Inc., based in San Diego, USA.

Dr Klassen brings nearly 14 years of industry experience to Sanifit and five years prior to this in Nephrology as a faculty member at Duke. He brings with him experience of taking a drug all the way through to approval at the FDA. In addition to his CMO role within the company, Dr Klassen will serve as President of the US subsidiary and his primary responsibilities will include leading the clinical development of SNF472 and enhancing the Company’s growing presence in the US. Dr Klassen is the first of the new hires planned by Sanifit as the Company establishes its US office based in San Diego.

Commenting on the appointment, Joan Perelló, CEO of Sanifit said,

“We are extremely fortunate to have someone of Preston’s experience join our leadership team. His first class operational and clinical development expertise in nephrology and cardiometabolic drug development, coupled with his leadership experience, will be invaluable in taking our lead product through to regulatory approval.

“Furthermore, we are very pleased to announce the opening of our US subsidiary, Sanifit Inc. The appointment of Preston and the opening of our new office in San Diego provide a robust platform for Sanifit’s growth strategy as we expand into the US.”

Dr Klassen added,

“I am excited to join the highly experienced team at Sanifit, and to assume responsibility for leading the development of its primary asset, SNF472, in the treatment of cardiovascular diseases linked to calcification, including patients with End Stage Renal Disease (ESRD) undergoing haemodialysis, for which there are currently no approved drugs, and the orphan drug program for calciphylaxis.”

Dr Klassen was most recently Executive Vice President, Head of Global Development at Orexigen Therapeutics. Previously, Dr Klassen held several positions of increasing responsibility at Amgen, Inc., including Therapeutic Area Head for Nephrology.

Prior to joining Amgen, Dr Klassen was a faculty member in the Division of Nephrology at Duke University Medical Center from 1997 to 2002. Dr Klassen received his M.D. from the University Of Nebraska College Of Medicine and completed his residency in Internal Medicine, fellowship in Nephrology, and M.H.S. degree at Duke University.

The announcement follows the recent appointment of Keith R. Leonard, Former President & CEO of Kythera Biopharmaceuticals, to Sanifit’s Board of Directors.


For media enquiries:

Joan Perelló
CEO Sanifit

Hume Brophy
Supriya Mathur, Elle Kress
Tel: +44 (0) 20 7862 6475

About SNF472

SNF472 is an intravenous formulation with a novel mechanism of action for haemodialysis patients with cardiovascular diseases linked to calcification. SNF472 is being developed for two indications: reduction of cardiovascular events in dialysis patients and for the treatment of calciphylaxis. SNF472 has orphan drug status for the treatment of calciphylaxis from both the EMA and FDA. SNF472 selectively blocks the pathological cardiovascular calcification progression and poses an innovative solution for these unmet medical needs. The intravenous route is promising for dialysis patients as it assures 100% compliance.

About Sanifit

Sanifit is a biopharmaceutical company focused on the development of SNF472. The company was founded in 2007 as a spin-off of the University of the Balearic Islands. SNF472 is an experimental drug for the treatment of cardiovascular diseases linked to calcification in the End Stage Renal Disease population undergoing haemodialysis. Sanifit has completed phase 1a studies with healthy volunteers in 2014. It is currently concluding a phase Ib/IIa study in haemodialysis patients. After a recent series C funding round of $41.3M (€36.6M), Sanifit will start a phase IIb study in ESRD and extend the orphan program in calciphylaxis into phase II/III clinical trials. For more information please visit

Gilde Healthcare company NIZO acquires lactic acid facility and strengthens partnership with DSM-firmenich

NIZO food research B.V. (“NIZO”) is proud to announce the signature of a long-term contract manufacturing partnership with dsm-firmenich. This strategic alliance encompasses the acquisition of the neighboring lactic acid facility from Vika Nutrition B.V.,...
February 29, 2024

Gilde Healthcare co-leads oversubscribed €54 Million Series B round of Argá Medtech

Argá Medtech, a company developing a next-generation cardiac ablation system for treating cardiac arrhythmias, including atrial fibrillation (AF), announced it closed a €54M oversubscribed Series B raise co-led by Gilde Healthcare with existing investors, Advent...
February 28, 2024

Gilde Healthcare leads $125 Million Equity Financing of Mainstay Medical

Funding to accelerate commercial growth and expand clinical and health economic evidence for ReActiv8® Restorative NeuromodulationTM System Mainstay Medical Holdings plc today announced an equity financing in which it will receive gross proceeds of US$125...
February 27, 2024